Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease.

[1]  A. L'Abbate,et al.  Long-term prognosis in stable angina; medical treatment or coronary revascularization in patients younger than 70 years? , 2011, International journal of cardiology.

[2]  Zhi-min He,et al.  Improvement of endothelial dysfunction in atherosclerotic rabbit aortas by ex vivo gene transferring of dimethylarginine dimethylaminohydrolase-2. , 2010, International journal of cardiology.

[3]  A. Coats,et al.  Ethics in the authorship and publishing of scientific articles , 2010 .

[4]  A. Goette,et al.  The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA. , 2010, International journal of cardiology.

[5]  G. Sesti,et al.  Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. , 2010, International journal of cardiology.

[6]  Qingbo Xu,et al.  Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21–Dependent Mechanism , 2010, Circulation research.

[7]  V. Chopra,et al.  Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. , 2010, Atherosclerosis.

[8]  F. Palm,et al.  Cellular ADMA: regulation and action. , 2009, Pharmacological research.

[9]  Renke Maas,et al.  Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. , 2007, International journal of cardiology.

[10]  D. Tsikas,et al.  Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography-mass spectrometry as pentafluorobenzamide derivative: evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  T. Lüscher,et al.  Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. , 2007, Atherosclerosis.

[12]  W. März,et al.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.

[13]  D. Tsikas,et al.  Effects of asymmetric dimethylarginine (ADMA) infusion in humans , 2006, European Journal of Clinical Pharmacology.

[14]  D. Tsikas,et al.  Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study , 2006, European Journal of Clinical Pharmacology.

[15]  H. Klemm,et al.  Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. , 2005, European urology.

[16]  P. Poole‐Wilson,et al.  Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. , 2005, Journal of the American College of Cardiology.

[17]  E. Schwedhelm,et al.  Determination of a reference value for NG, NG‐dimethyl‐L‐arginine in 500 subjects , 2005, European journal of clinical investigation.

[18]  R. Schnabel,et al.  Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study , 2005, Circulation research.

[19]  T. Meinertz,et al.  Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. , 2005, European heart journal.

[20]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  Sang Hoon Lee,et al.  Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. , 2005, The American journal of cardiology.

[22]  A. Duits,et al.  Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease , 2005, Annals of Hematology.

[23]  R. Böger.  Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. , 2004, The Journal of nutrition.

[24]  D. Tsikas,et al.  Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  T. Münzel,et al.  ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.

[26]  P. Vallance,et al.  The DDAH/ADMA/NOS pathway. , 2003, Atherosclerosis. Supplements.

[27]  JamesLeiper,et al.  Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase , 2003 .

[28]  R. Boger.  T he emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor , 2003 .

[29]  K. Fox,et al.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial , 2002, The Lancet.

[30]  C. Zoccali,et al.  Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[31]  J. Cooke,et al.  Does ADMA cause endothelial dysfunction? , 2000, Arteriosclerosis, thrombosis, and vascular biology.